Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa

被引:198
作者
Barnes, KI [1 ]
Durrheim, DN
Little, F
Jackson, A
Mehta, U
Allen, E
Dlamini, SS
Tsoka, J
Bredenkamp, B
Mthembu, DJ
White, NJ
Sharp, BL
机构
[1] Univ Cape Town, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa
[2] Hunter New England Populat Hlth, Hlth Protect, Newcastle, NSW, Australia
[3] Univ Cape Town, Dept Stat Sci, ZA-7925 Cape Town, South Africa
[4] MRC, Malaria Lead Res Programme, Durban, South Africa
[5] Mahidol Univ, Fac Trop Med, Bangkok 10700, Thailand
[6] Churchill Hosp, Ctr Vaccinol & Trop Med, Oxford OX3 7LJ, England
基金
英国惠康基金;
关键词
D O I
10.1371/journal.pmed.0020330
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Between 1995 and 2000, KwaZulu-Natal province, South Africa, experienced a marked increase in Plasmodium falciparum malaria, fuelled by pyrethroid and sulfadoxine-pyrimethamine resistance. In response, vector control was strengthened and artemether-lumefantrine (AL) was deployed in the first Ministry of Health artemisinin-based combination treatment policy in Africa. In South Africa, effective vector and parasite control had historically ensured low-intensity malaria transmission. Malaria is diagnosed definitively and treatment is provided free of charge in reasonably accessible public-sector health-care facilities. Methods and Findings We reviewed four years of malaria morbidity and mortality data at four sentinel health-care facilities within KwaZulu-Natal's malaria-endemic area. In the year following improved vector control and implementation of AL treatment, malaria-related admissions and deaths both declined by 89%, and outpatient visits decreased by 85% at the sentinel facilities. By 2003, malaria-related outpatient cases and admissions had fallen by 99%, and malaria-related deaths had decreased by 97%. There was a concomitant marked and sustained decline in notified malaria throughout the province. No serious adverse events were associated causally with AL treatment in an active sentinel pharmacovigilance survey. In a prospective study with 42 d follow up, AL cured 97/98 (99%) and prevented gametocyte developing in all patients. Consistent with the findings of focus group discussions, a household survey found self-reported adherence to the six-dose AL regimen was 96%. Conclusion Together with concurrent strengthening of vector control measures, the antimalarial treatment policy change to AL in KwaZulu-Natal contributed to a marked and sustained decrease in malaria cases, admissions, and deaths, by greatly improving clinical and parasitological cure rates and reducing gametocyte carriage.
引用
收藏
页码:1123 / 1134
页数:12
相关论文
共 49 条
  • [1] Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8
  • [2] Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children:: a randomised, multicentre trial
    Adjuik, M
    Agnamey, P
    Babiker, A
    Borrmann, S
    Brasseur, P
    Cisse, M
    Cobelens, F
    Diallo, S
    Faucher, JF
    Garner, P
    Gikunda, S
    Kremsner, PG
    Krishna, S
    Lell, B
    Loolpapit, M
    Matsiegui, PB
    Missinou, MA
    Mwanza, J
    Ntoumi, F
    Olliaro, P
    Osimbo, P
    Rezbach, P
    Some, E
    Taylor, WRJ
    [J]. LANCET, 2002, 359 (9315) : 1365 - 1372
  • [3] Baker L, 2001, S AFR MED J, V91, P358
  • [4] Bloland PB, 2000, B WORLD HEALTH ORGAN, V78, P1378
  • [5] A contrarian view of malaria therapy policy in Africa
    Bloland, PB
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2003, 68 (02) : 125 - 126
  • [6] Bredenkamp BLF, 2001, SAMJ S AFR MED J, V91, P970
  • [7] Exploring 30 years of malaria case data in KwaZulu-Natal, South Africa: Part II. The impact of non-climatic factors
    Craig, MH
    Kleinschmidt, I
    Le Sueur, D
    Sharp, BL
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2004, 9 (12) : 1258 - 1266
  • [8] Craig MH, 2004, TROP MED INT HEALTH, V9, P1247, DOI 10.1111/j.1365-3156.2004.01340.x
  • [9] Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial
    Dorsey, G
    Njama, D
    Kamya, MR
    Cattamanchi, A
    Kyabayinze, D
    Staedke, SG
    Gasasira, A
    Rosenthal, PJ
    [J]. LANCET, 2002, 360 (9350) : 2031 - 2038
  • [10] Drug combinations for malaria: time to ACT?
    Duffy, PE
    Mutabingwa, TK
    [J]. LANCET, 2004, 363 (9402) : 3 - 4